## (19) World Intellectual Property Organization

International Bureau



## 

(43) International Publication Date 15 April 2004 (15.04.2004)

**PCT** 

# (10) International Publication Number $WO\ 2004/031175\ A3$

(51) International Patent Classification<sup>7</sup>: C07D 401/14, 401/04, 213/80, A61K 31/444, A61P 3/04

(21) International Application Number:

PCT/JP2003/012290

(22) International Filing Date:

25 September 2003 (25.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2002-287015 30 September 2002 (30.09.2002) JP 2002-353202 5 December 2002 (05.12.2002) JP

(71) Applicant (for all designated States except US): BANYU PHARMACEUTICAL CO., LTD. [JP/JP]; 2-3, Nihombashi Honcho 2-chome, Chuo-ku, Tokyo 103-8416 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SATO, Nagaaki [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). ANDO, Makoto [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). ISHIKAWA, Shiho [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). NAGASE, Tsuyoshi [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3,

Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). NAGAI, Keita [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP). KANATANI, Akio [JP/JP]; c/o BANYU PHARMACEUTICAL CO., LTD., Tsukuba Research Institute, 3, Okubo, Tsukuba-shi, Ibaraki 300-2611 (JP).

(74) Agent: IWATANI, Ryo; Sakurabashi Chiyoda Building, 5F, 1-27, Dojima 2-chome, Kita-ku, Osaka-shi, Osaka 530-0003 (JP).

(81) Designated States (national): AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN,

[Continued on next page]

### (54) Title: N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS



(57) Abstract: A compound of the formula (I): (wherein Ar<sup>11</sup> and Ar<sup>2</sup> are independently aryl or heteroaryl, any of which is optionally substituted by a substituent selected from the group consisting of cyano, halogen, nitro, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, cyclo-lower alkyl, cyclo(lower alkyl) -lower alkyl, lower alkenyl, lower alkylamino, di-lower alkylamino, lower alkanoylamino, lower alkylsulfonylamino, arylsulfonylamino, hydroxy, lower alkoxy, halo-lower alkoxy, aryloxy, heteroaryloxy, lower alkylthio, carboxyl, formyl, lower alkanoyl, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylsulfonyl, arylsulfonyl, aryl and heteroaryl; R¹and R²are independently lower alkyl, cyclo-lower alkyl, cyclo(lower alkyl)-lower alkyl or lower alkoxy, any of which is optionally substituted by a substituent selected from the group consisting of halogen,

lower alkylamino, di-lower alkylamino, lower alkanoylamino, hydroxy, lower alkoxy, f ormyl, lower alkoxycarbonyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl; R<sup>1</sup>, R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, cyano, halogen hydroxy, or lower alkyl, lower alkoxy or lower alkylthio, the last three groups being optionally substituted by a substituent selected from the group consisting of halogen, lower alkylamino, di-lower alkylamino, lower alkanoylamino, hydroxy, lower alkoxy, formyl, lower alkoxycarbonyl, lower alkylcarbamoyl and di-lower alkylcarbamoyl), or a salt or ester thereof is useful as a neuropeptide Y receptor antagonist agent and is also useful as an agent for the treatment of bulimia, obesity or diabetes.

## WO 2004/031175 A3



MX, NI, NO, NZ, OM, PG, PH, PL, RU, SC, SG, SY, TJ, TM, TN, TT, UA, UZ, VC, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

### **Published:**

with international search report

## (88) Date of publication of the international search report: 24 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No PCT/JP 03/12290

Relevant to claim No.

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D401/14 C07D401/04 C07D213/80 A61K31/444 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Category °

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

WO 01/062738 A (BANYU PHARMA (;KANATANI AKIO (JP); NAGAI KE: OKAMOTO) 30 August 2001 (2001-cited in the application the whole document & US 2003/158418 A1 21 August 2003 (2003-08-21)	ITA (JP);	1-41,44, 45
DATABASE CROSSETRE BETLISTEIN		
Beilstein Institut zur Förder	ung der	42,43
er documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
agories of cited documents:  In the defining the general state of the art which is not be red to be of particular relevance soument but published on or after the international state.  It which may throw doubts on priority claim(s) or solied to establish the publication date of another or other special reason (as specified)  In referring to an oral disclosure, use, exhibition or the eans at published prior to the international filing date but an the priority date claimed	or priority date and not in conflict with cited to understand the principle or the invention  "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvio in the art.	the application but early underlying the claimed invention to be considered to cument is taken alone claimed invention ventive step when the pre other such docuus to a person skilled
ctual completion of the international search	Date of mailing of the international sea	rch report
December 2003	22 04 20	004
ailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer  Grassi, D	
	Chemischen Wissenschaften, Fra Main, DE; XP002265820 Database accession no. 150480 abstract  er documents are listed in the continuation of box C.  egories of cited documents:  It defining the general state of the art which is not red to be of particular relevance ocument but published on or after the international tet which may throw doubts on priority claim(s) or cited to establish the publication date of another or other special reason (as specified)  It referring to an oral disclosure, use, exhibition or eans It published prior to the international filling date but in the priority date claimed  Citual completion of the international search  December 2003  alling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Chemischen Wissenschaften, Frankfurt am Main, DE; XP002265820 Database accession no. 150480 abstract  -/  Product documents are listed in the continuation of box C.  Iggories of cited documents: It defining the general state of the art which is not red to be of particular relevance comment but published on or after the international relevance in the publication date of another or or other special reason (as specified) In the prior to the international filing date but in the prior to the international search  December 2003  Authorized officer  Authorized officer  Frankfurt am  Parankfurt  Parankfur

International Application No
PCT/JP 03/12290

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
& BRADLOW ET AL.: "The oxidation of some beta-substituted pyridine alkoxides" J. ORG. CHEM., vol. 16, 1950, pages 73-83,	
•	
	ORG. CHEM., vol. 16, 1950, pages 73-83,

International Application No PCT/JP 03/12290

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-41,44,45
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-41,44,45

Compounds of formula (I), their preparation and use.

2. claims: 42,42

Intermediates according to formula III-1 (the different alternatives encompassed by these claims appear still not to be unitary, however, the claims could be searched without extra effort).

Information on patent family members

International Application No
PCT/JP 03/12290

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9948887	Α	30-09-1999	AU	757488 B2	20-02-2003
NO 33 10007	••	00 03 2005	AU	2888899 A	18-10-1999
			AU	757290 B2	13-02-2003
			ΑÜ	2888999 A	18-10-1999
			ΑU	757252 B2	13-02-2003
			AU	2889099 A	18-10-1999
			CA	2325472 A1	30-09-1999
			CA	2325587 A1	30-09-1999
			CA	2325588 A1	30-09-1999
			EP	1066278 A1	10-01-2001
			EP	1066279 A1	10-01-2001
			ΕP	1066262 A1	10-01-2001
			JP	2002507603 T	12-03-2002
			JP	2002507610 T	12-03-2002
			JP	2002507611 T	12-03-2002
			MO	9948887 A1	30-09-1999
			MO	9948888 A1	30-09-1999
			WO	9948873 A1	30-09-1999
			US	6063934 A	16-05-2000
			US	6096745 A	01-08-2000
			US	6054590 A	25-04-2000
WO 0162738	Α	30-08-2001	ΑU	3412801 A	03-09-2001
			CA	2400659 A1	30-08-2001
			EP	1264826 A1	11-12-2002
			WO	0162738 A1	30-08-2001
			US	2003158418 A1	21-08-2003
US 2003158418	A1	21-08-2003	 AU	3412801 A	03-09-2001
			CA	2400659 A1	30-08-2001
			ΕP	1264826 A1	11-12-2002
			WO	0162738 A1	30-08-2001